Xenon Pharmaceuticals (XENE) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free XENE Stock Alerts $40.45 -0.13 (-0.32%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 9:15 PM | markets.businessinsider.comBuy Rating Affirmed: Xenon’s Strategic Advancements in MDD Development and Diversified PipelineMay 12 at 2:56 AM | americanbankingnews.comWedbush Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $50.00May 12 at 2:22 AM | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Reaffirmed by Needham & Company LLCMay 12 at 2:22 AM | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $60.00May 11, 2024 | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesMay 11, 2024 | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down on Analyst DowngradeMay 10, 2024 | finance.yahoo.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comCitigroup Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $60.00Citigroup lowered their price objective on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a "buy" rating for the company in a research report on Friday.May 10, 2024 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $62.00 price objective on shares of Xenon Pharmaceuticals in a research report on Friday.May 10, 2024 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Announces Earnings Results, Beats Estimates By $0.07 EPSXenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.07. The company had revenue of $1.00 million during the quarter. During the same quarter in the prior year, the firm earned ($0.63) EPS. The firm's revenue was up .0% compared to the same quarter last year.May 10, 2024 | finance.yahoo.comXenon Pharmaceuticals Inc (XENE) Reports Increased Losses in Q1 2024, Despite Advancements in ...May 10, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)May 10, 2024 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down Following Analyst DowngradeXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down on Analyst DowngradeMay 9, 2024 | washingtonpost.comXenon Pharmaceuticals: Q1 Earnings SnapshotMay 9, 2024 | msn.comXENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024May 9, 2024 | globenewswire.comXenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by TimesSquare Capital Management LLCTimesSquare Capital Management LLC increased its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 34.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 793,954 shares of theMay 8, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024May 8, 2024 | globenewswire.comPolarean's Xenon MRI to be Featured at Upcoming ATS 2024 ConferenceMay 8, 2024 | americanbankingnews.comXenon Pharmaceuticals (XENE) Scheduled to Post Earnings on ThursdayMay 7, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceMay 3, 2024 | marketbeat.comXenon Pharmaceuticals (XENE) Set to Announce Earnings on ThursdayXenon Pharmaceuticals (NASDAQ:XENE) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | globenewswire.comXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate UpdateApril 30, 2024 | marketbeat.comabrdn plc Acquires Shares of 32,036 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)abrdn plc bought a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 32,036 shares of the biopharmaceutical company's stock, valued at approximately $1,476,000. SApril 25, 2024 | marketbeat.comJennison Associates LLC Buys 352,573 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Jennison Associates LLC lifted its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 164.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 566,396 shares of the biopharmaceuticalApril 23, 2024 | marketbeat.comFederated Hermes Inc. Invests $15.96 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Federated Hermes Inc. bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 346,596 shares of the biopharmaceutical companApril 16, 2024 | globenewswire.comXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual MeetingApril 12, 2024 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)Needham & Company LLC reiterated a "buy" rating and issued a $62.00 target price on shares of Xenon Pharmaceuticals in a research note on Friday.April 10, 2024 | investing.comXenon Pharmaceuticals Inc (XENE)April 10, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 4, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | marketbeat.comSG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)SG Americas Securities LLC reduced its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 67.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,606 shares of the biopharmaceutical comApril 1, 2024 | marketbeat.comAssenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Assenagon Asset Management S.A. trimmed its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 32.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 99,731 shares of the biopharmaceutical company's stocMarch 21, 2024 | money.usnews.comXenon Pharmaceuticals IncMarch 19, 2024 | finance.yahoo.comXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth PlansMarch 19, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Wellington Management Group LLPWellington Management Group LLP boosted its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 64.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,728,108 shares of the biopharmaceuticalMarch 16, 2024 | finance.yahoo.comXENE Apr 2024 47.500 putMarch 15, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Boosted by Walleye Capital LLCWalleye Capital LLC increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 40.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,028 shares of the biopharmaceutical coMarch 12, 2024 | globenewswire.comXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysMarch 12, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Qube Research & Technologies LtdQube Research & Technologies Ltd grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 81.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 54,285 shares of the biopharmaceutical company's stock after purchaMarch 11, 2024 | marketbeat.comTimesSquare Capital Management LLC Has $20.17 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)TimesSquare Capital Management LLC lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 38.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 590,575 shares of the biophaMarch 11, 2024 | insidertrades.comInsider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of StockMarch 9, 2024 | finance.yahoo.comInsider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...March 8, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells $330,300.36 in StockXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) EVP Sherrington Robin sold 7,137 shares of the business's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $330,300.36. Following the sale, the executive vice president now directly owns 8,398 shares in the company, valued at approximately $388,659.44. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.March 8, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 120,000 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Adage Capital Partners GP L.L.C. cut its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 17.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 550,000 shares of the biopharmaceutical company's stock after selling 120,000 shaMarch 7, 2024 | marketbeat.comCantor Fitzgerald Weighs in on Xenon Pharmaceuticals Inc.'s FY2024 Earnings (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Analysts at Cantor Fitzgerald raised their FY2024 earnings estimates for Xenon Pharmaceuticals in a note issued to investors on Monday, March 4th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the biopharmaceutical company will eMarch 5, 2024 | globenewswire.comXenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024March 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline ProgressMarch 2, 2024 | seekingalpha.comXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide XENE Media Mentions By Week XENE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XENE News Sentiment▼0.420.55▲Average Medical News Sentiment XENE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XENE Articles This Week▼233▲XENE Articles Average Week Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IDEAYA Biosciences News Janux Therapeutics News HUTCHMED News Arrowhead Pharmaceuticals News Amicus Therapeutics News Prestige Consumer Healthcare News Ultragenyx Pharmaceutical News Axsome Therapeutics News Biohaven News Merus News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XENE) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDoes this make you sick?Allegiance GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
